Sarepta Therapeutics Inc
$ 21.73
-1.90%
15 Apr - close price
- Market Cap 2,281,428,000 USD
- Current Price $ 21.73
- High / Low $ 22.49 / 21.55
- Stock P/E N/A
- Book Value 10.87
- EPS -7.13
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.54 %
- 52 Week High 64.80
- 52 Week Low 10.41
About
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$21.78
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-03 | 2025-08-06 | 2025-04-29 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-01 | 2024-02-28 | 2023-11-01 | 2023-08-02 | 2023-05-02 |
| Reported EPS | -3.58 | -0.13 | 2.02 | -3.42 | 1.9 | 0.34 | 0.07 | 0.37 | 0.47 | -0.46 | -0.27 | -5.86 |
| Estimated EPS | -1.05 | -0.6985 | 0.7 | -0.6494 | 2.0603 | -0.13 | 0.01 | -0.07 | 0.01 | -1.23 | -1.78 | -1.38 |
| Surprise | -2.53 | 0.5685 | 1.32 | -2.7706 | -0.1603 | 0.47 | 0.06 | 0.44 | 0.46 | 0.77 | 1.51 | -4.48 |
| Surprise Percentage | -240.9524% | 81.3887% | 188.5714% | -426.64% | -7.7804% | 361.5385% | 600% | 628.5714% | 4600% | 62.6016% | 84.8315% | -324.6377% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.39 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRPT
2026-04-16 06:34:00
Sarepta Therapeutics' stock rose above its 200-day moving average, signaling increased investor confidence despite mixed analyst ratings. This surge is attributed to the biotech firm's progress in developing treatments for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. Investors are keenly watching the company's continued momentum, pipeline developments, and upcoming regulatory milestones.
2026-04-13 22:09:21
This article reports a significant decrease in the price target for Sarepta Therapeutics (SRPT). The target has been lowered by 16.58% to $25.25. The content is very brief, providing only this financial update.
2026-04-12 09:09:42
The article reports that the price target for Sarepta Therapeutics (SRPT) has been decreased by 16.58% to $25.25. No further details or reasons for this change are provided in the available content.
2026-04-10 09:09:26
Sarepta Therapeutics (SRPT) has experienced recent share price volatility, with a 1.5% daily gain but a 4.3% weekly decline, yet a 25.9% monthly rise. The market narrative suggests SRPT is 3% overvalued at $22.23, with a consensus analyst price target of $21.65. However, a Discounted Cash Flow (DCF) model indicates a significantly higher estimated value of $75.53 per share, presenting a divergence in valuation perspectives.
2026-04-09 20:09:26
This article reports a significant decrease in the price target for Sarepta Therapeutics (SRPT). The target has been lowered by 16.58% to 25.25. However, due to the brevity of the provided content, further details regarding the reasons for this change are not available.
2026-04-09 08:39:37
This article provides an analysis of Sarepta Therapeutics Inc. (SRPT) financials, including its revenue breakdown, profitability margins, and a comparison with competitors. The company's primary revenue driver is PMO Products, contributing 59.7% of total sales. Despite a gross margin of 47.15%, SRPT exhibits negative operating and net margins, along with a negative Return on Equity.
